ContraFect's CF-301 gets Fast Track designation

ContraFect Corp. (NASDAQ:CFRX) gained $0.83 (18%) to $5.39 on Monday after FDA granted Fast Track designation to CF-301, a lysin targeting Staphylococcus aureus. ContraFect began a Phase I study in A...